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development and special grant programs are available in the USA and Japan. Only in 
South Korea, products that have already obtained orphan designation in elsewhere 
can benefit from a partial exemption from dossier submission for orphan designa-
tion and market authorization. ConClusions: OD regulation and incentives are 
similar by nature but differ in magnitude. It is unclear how the profitability criteria 
are applied in US as multiple orphan products are blockbuster. USA applies the 
mildest criteria for granting orphan status and provides the greatest financial sup-
port. The financial assistance is the most modest in the EU while exclusivity is the 
longest. EU adds an additional layer at member state level.
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objeCtives: In order to stimulate the research and development of orphan drugs, in 
2000 the EU introduced new legislation with the aim of providing incentives for the 
development of drugs for rare disorders. One of the strongest incentives, regarding 
experience in the United States of America and Japan, is a market exclusivity period 
post authorization for designated products. The objective of this study is to assess if 
the 10 year market exclusivity has created a market failure by assessing the prices 
and the competition environment of drugs for which this period has come to an 
end. Methods: From the 2014 Orphanet’s list, we retrieved the 20 drugs that have 
lost their market exclusivity for at least one indication (26 indications). It is worth to 
note that some of them still have market exclusivity for another indication, which 
means they may still be on the orphan drug register. We focused on the French mar-
ket and used French administrated prices. Results: 63% (12 drugs) of the sample 
have not suffered a drop in prices after the market exclusivity loss. Among all the 
studied variables, the most important event to trigger a price drop seems to be an 
extension of indication. 40% (10 drugs) of the sample were able to see the arrival 
of competitors during their period of market exclusivity even if they target a small 
population. ConClusions: These results show that the market exclusivity does 
not necessarily create an inflationary effect and a monopoly for orphan drugs. 
Market exclusivity would act as a protectionist measure. Its major interest is in the 
beginning of the product’s life and for old drugs for which the molecule is not under 
the patent at the time of the approval.
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objeCtives: The use of cost effectiveness analysis for treatments for rare diseases 
has proved difficult and alternative frameworks for assessing value and determin-
ing pricing and reimbursement have been sought. Here we summarise rare disease 
specific methodologies proposed in the literature. Methods: A systematic litera-
ture review of Medline and EMBASE databases was conducted for the period 2000 
– 2014 without geographic restriction. The search sought to identify papers that 
proposed specific frameworks for a) assessing the value of rare disease treatments 
or b) determining the price or reimbursement status of such drugs. Policy papers, 
commentaries, and review articles were included. Clinical or economic studies of 
specific rare diseases and their treatments were excluded. Results: The litera-
ture review identified 1,034 papers. Eleven studies proposed specific methods for 
assessing rare disease treatments. The most commonly proposed approach (7 of 
11 papers) involved multi-criteria decision analysis. Of these studies, 5 proposed 
MCDA frameworks; one study applied and validated MCDA frameworks with rare 
disease stakeholders and another study investigated the relationship between 
MCDA domain attributes and the cost of rare disease drugs. Of non-MCDA meth-
ods, one study described a novel decision making framework that balances payer 
value factors with opportunity cost, and another discussed a policy framework for 
funding rare disease treatments in Ontario. Two studies specified non-value based 
pricing frameworks: one cost-based pricing and another ‘grant and access’ pricing. 
Limitations included challenges identifying representative societal preferences, 
determining the perspective from which value should be assessed, and resistance to 
transparency from decision makers. ConClusions: The need for a new framework 
for the evaluation of rare disease treatments has been commonly recognised in the 
published literature. A number of authors have proposed alternative approaches to 
cost effectiveness, but practical challenges are limiting their application currently.
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objeCtives: The aim of this study was to review and compare decisions of par-
ticular European HTA Agencies as well as orphan drugs’ reimbursement status in 
corresponding countries. Methods: 93 orphan drugs, approved in Europe, were 
identified. We considered the following European HTA Agencies: AOTM (Poland), 
NICE (England), AWMSG (Wales), HAS (France), SMC (Scotland), IQWIG (Germany). 
Data on the Agencies’ recommendations (positive, negative, conditional) and reim-
bursement status were collected for each drug. Results: Among all identified 
orphan drugs 18%-60% were assessed by the HTA Agencies in particular countries. 
AWMSG assessed 56 orphans, and IQWIG only 17 drugs. Among 93 orphan drugs 
23 (25%) have never been assessed by any of analyzed European HTA Agencies. 
The average rates of positive, negative and conditional recommendations among 
included Agencies were 51.6%, 39.4% and 9.0%, respectively. The highest rate of 
positive recommendations was obtained by HAS Agency (France) which was 89.4%, 
and the lowest by AOTM (Poland) - 17.9%, but AOTM has issued also 42.9% condi-
tional recommendations. On average, 13% of approved orphan drugs are reimbursed 
In contrast, there are strong differences in the reimbursement of orphan drugs in 
Nordic and devolved markets. Relevant stakeholders in reimbursement assessment 
are national HTA (health technology assessment) agencies or regional authorities. 
In all archetypes, except health insurance markets, regional authorities are the 
relevant funding stakeholders. ConClusions: There are several similarities and 
differences in orphan drug reimbursement across European countries. While some 
countries do not differentiate between orphan and non-orphan drugs in decision-
making or funding, others have implemented specific policies.
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objeCtives: The present work reviews current practices for the definition of the reim-
bursed price of orphan drugs, and proposes a conceptual framework for their value-
based pricing along with a roadmap for its possible implementation. Methods: 
Based on a literature analysis, we systematize the current discussions on the topic 
within a conceptual framework intended to support evaluations and decision-making 
for determining a value-based reimbursed price for orphan drugs. Results: Our anal-
ysis points out the “black box” pricing mechanism of orphan drugs and the limited 
consistency of some of the constituent domains of Health Technology Assessment 
when applied to orphan medical products (safety, clinical effectiveness, costs and 
economic evaluation, ethical analysis, and organizational and social aspects). The 
proposed framework comprises: a) elements of societal value and methods for its 
assessment, b) exchanges of valuable and trustworthy information between relevant 
stakeholders from an early stage, c) innovative reimbursement approaches to balance 
the need for evidence-based decisions with timely access to innovative drugs for 
patients with rare diseases, d) societal participation in the risky entrepreneurship of 
producing orphan drugs. Considering the areas reported in the proposed framework, 
we identified a possible roadmap for its implementation via three critical phases: i) 
sharing available experiences, ii) integrating and systematizing methods for appro-
priate use, iii) identifying delegate agencies. ConClusions: Additional piloting of 
emerging experiences and sharing of implementations developed worldwide are 
needed, along with the identification of an internationally agreed-upon taxonomy 
and pan-national recognised subjects to be delegated part of the HTA activities cur-
rently spread over a multiplicity of subjects.
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objeCtives: In 2000 EU introduced an orphan legislation in order to stimulate 
the development of drugs for rare diseases. Nevertheless, the actual availability of 
orphan drugs (ODs) in the EU depends on national authorities. The study aims to 
compare OD availability and market access in France and the UK. Methods: The 
details on OD prices and reimbursement were extracted from Ameli database in 
France and British National Formulary in the UK. The molecules were considered 
available if the price were published. NICE recommendations were extracted from 
the official website. Results: 55 and 56 ODs were available in the UK and France, 
respectively, among 82 ODs authorized in the EU. 50 ODs were available in the two 
countries. Most of ODs sold in pharmacy were 100% or 65% reimbursed in France. 
All drugs are 100% reimbursed in the UK and when used in hospital in France. 
Only 20 ODs were assessed by the NICE in 24 indications. In 10 cases NICE did not 
recommend the drug, in five cases the indication was restricted. For more than 
60% of molecules prices were higher in the UK. The median difference was about 
10%. ConClusions: The number of commercialized ODs is similar in the two 
countries. However, given the fact that most of ODs has not been recommended by 
the NICE, it is unlikely that they will be prescribed. Prices are free of control in the 
UK leading to higher prices compared with France. Although prices are published 
in the both countries, the real prices are impacted by implementing patient access 
schemes in the UK and hidden volume agreements in France. Interestingly, while 
cost-effectiveness assessment is becoming mandatory in France, NICE introduces 
a new methodology for OD moving away from economic evaluation.
PSY111
orPhan drug rEgulation in thE uSa, EuroPEan union, JaPan and 
South korEa: a comParativE analYSiS
Tomita N1, Lee H2, Korchagina D3, Toumi M4, Rémuzat C5, Falissard B6
1National Institute of Public Health, Saitama, Japan, 2Seoul National University College of 
Medicine, Seoul, South Korea, 3University of Paris-Sud, Paris, France, 4Aix-Marseille University, 
Marseille, France, 5Creativ-Ceutical, Paris, France, 6Maison de Solenn, Paris, France
objeCtives: The study aims to review and compare orphan drug (OD) policies in 
the USA, EU, Japan and South Korea. Methods: The OD policies (regulation and list 
of incentives) were extracted from the official websites of the regulatory authori-
ties. Results: USA was the first to implemented OD legislation in 1983, followed 
by Japan (1993), South Korea (1997), and the EU (2000). The prevalence threshold 
is the highest in the USA and the lowest in Japan. The rarity of the disease or the 
lack of profitability is the only criteria for granting orphan status in the USA. In 
the EU, Japan and South Korea high unmet needs should be demonstrated. Some 
non-rare conditions are eligible for orphan designation in Japan and South Korea. 
Development feasibility needs to be proven in Japan. Specific scientific assistance 
is available in all regions except South Korea. Market exclusivity is granted for 
10 years in the EU and 7 years in the USA. Financial assistance through fees reduc-
tion is available in all geographies. All regions but the EU also provide fast track 
marketing authorization procedure. Tax credits and/or tax reduction for clinical 
